Kayothera, Inc.

Seattle, WA

UEI
RPZEUH63MQA3
CAGE
8DJW5
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
2815 Eastlake Ave E #300, Seattle, WA 98102, USA
Website
kayothera.com
Founded
2019
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Consumer Discretionary
  2. Media
  3. Publishing
SIC code
27 Printing & Publishing
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of first-in-class antagonists of the retinoid pathway as novel oral therapies for type 2 diabetes R43DK136420 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $337,609
Development of first-in-class antagonists of the retinoid pathway as novel oral immunotherapies for solid cancers R43CA278127 National Cancer Institute (NIH) $398,040

Quick answers

Is Kayothera, Inc. registered in SAM.gov?

Yes. Kayothera, Inc.'s SAM.gov registration is active through May 8, 2027.

What is Kayothera, Inc.'s most recent federal award?

Kayothera, Inc.'s most recent federal grant award is Development of first-in-class antagonists of the retinoid pathway as novel oral therapies for type 2 diabetes (R43DK136420), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on May 24, 2023.

On GovTribe

See Kayothera, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login